HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belani, C. P. Search for Related Content PubMed PubMed Citation Articles by Belani, C. P.

Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer^*

^* From the Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pittsburgh, PA.

Correspondence to: Chandra P. Belani, MD, University of Pittsburgh Cancer Institute, 200 Lothrop St, MUH N-725, Pittsburgh, PA 15213; e-mail: belanicp{at}msx.upmc.edu

Paclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25%, it was logical to examine the impact of paclitaxel in combination chemotherapy regimens. In trials evaluating the activity of paclitaxel in combination with one of the platinum compounds, cisplatin or carboplatin, response rates have ranged from 35 to > 50% and were significantly better than response rates observed with etoposide/cisplatin, the previous standard regimen for treatment of NSCLC. Docetaxel is a newer taxane that also has exhibited notable single-agent activity and response rates ranging from 20 to 50% when combined with cisplatin. Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease.

Key Words: carboplatin • cisplatin • docetaxel • non-small cell lung cancer • paclitaxel • taxanes

This article has been cited by other articles:

				N. V. Koshkina, J. C. Waldrep, L. E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastases in Murine Renal Carcinoma Model Clin. Cancer Res., October 1, 2001; 7(10): 3258 - 3262. [Abstract] [Full Text] [PDF]